- Home
- GILD vs QCOM Comparison
GILD vs QCOM Comparison
Compare GILD & QCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | QCOM |
|---|---|---|
| Founded | 1987 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 145.4B |
| IPO Year | 1992 | 1991 |
Fundamental Metrics
Financial Performance| Metric | GILD | QCOM |
|---|---|---|
| Price | $154.98 | $140.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 20 |
| Target Price | $141.56 | ★ $168.53 |
| AVG Volume (30 Days) | 8.8M | ★ 11.5M |
| Earning Date | 02-10-2026 | 02-04-2026 |
| Dividend Yield | 2.12% | ★ 2.53% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | 4.90 |
| Revenue | $29,443,000,000.00 | ★ $44,867,000,000.00 |
| Revenue This Year | $4.68 | $4.24 |
| Revenue Next Year | $5.11 | $1.21 |
| P/E Ratio | ★ $22.86 | $28.72 |
| Revenue Growth | 2.40 | ★ 10.25 |
| 52 Week Low | $93.37 | $120.80 |
| 52 Week High | $157.29 | $205.95 |
Technical Indicators
Market Signals| Indicator | GILD | QCOM |
|---|---|---|
| Relative Strength Index (RSI) | 70.71 | 33.04 |
| Support Level | $147.00 | $132.73 |
| Resistance Level | $157.29 | $142.39 |
| Average True Range (ATR) | 4.28 | 4.22 |
| MACD | 0.86 | -0.33 |
| Stochastic Oscillator | 88.30 | 32.86 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About QCOM QUALCOMM Incorporated
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G, 4G, and 5G networks. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones, as well as chips into automotive and Internet of Things markets.